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Abstract
The integrin v6 is up-regulated in numerous carcinomas, where expression commonly correlates with poor
prognosis. v6 promotes tumour invasion, partly through regulation of proteases and cell migration, and is also
the principal mechanism by which epithelial cells activate TGF-1; this latter function complicates therapeutic
targeting of v6, since TGF-1 has both tumour-promoting and -suppressive effects. It is unclear how these
different v6 functions are linked; both require actin cytoskeletal reorganization, and it is suggested that tractive
forces generated during cell migration activate TGF-1 by exerting mechanical tension on the ECM-bound latent
complex. We examined the functional relationship between cell invasion and TGF-1 activation in pancreatic
ductal adenocarcinoma (PDAC) cells, and confirmed that both processes are v6-dependent. Surprisingly, we
found that cellular functions could be biased towards either motility or TGF-1 activation depending on the
presence or absence of epidermal growth factor receptor pathway substrate 8 (Eps8), a regulator of actin
remodelling, endocytosis, and GTPase activation. Similar to v6, we found that Eps8 was up-regulated in
>70% of PDACs. In complex with Abi1/Sos1, Eps8 regulated v6-dependent cell migration through activation
of Rac1. Down-regulation of Eps8, Sos1 or Rac1 suppressed cell movement, while simultaneously increasing
v6-dependent TGF-1 activation. This latter effect was modulated through increased cell tension, regulated by
Rho activation. Thus, the Eps8/Abi1/Sos1 tricomplex acts as a key molecular switch altering the balance between
Rac1 and Rho activation; its presence or absence in PDAC cells modulates v6-dependent functions, resulting in a
pro-migratory (Rac1-dependent) or a pro-TGF-1 activation (Rho-dependent) functional phenotype, respectively.
© 2017 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
The epithelial-specific integrin αvβ6 is not expressed
in healthy tissue but is up-regulated during epithelial
remodelling, where it interacts with several ligands
including fibronectin, tenascin, vitronectin, and the
latency-associated peptide of TGF-β1 (LAP) and
TGF-β3 [1–3]. αvβ6 is up-regulated in numerous car-
cinomas, including pancreatic ductal adenocarcinoma
(PDAC [4–7]), and a high level of expression is
prognostic in several tumour types, including colorectal,
lung, and breast carcinomas [6,8,9]. Consistent with this,
αvβ6 promotes tumour cell invasion and metastasis,
partly by regulating multiple proteases [MMP-9,
MMP-2, MMP-13, and urokinase-type plasmino-
gen activator (uPA) [5,10]]. αvβ6 is also the principal
epithelial activator of TGF-β1 [3,11], interacting with its
latency-associated peptide to induce a conformational
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change in the latent complex to expose the active
cytokine [12,13]. The potential for the therapeutic
targeting of αvβ6 is complicated by its role in TGF-β1
activation. While TGF-β1 has numerous well-described
pro-tumourigenic effects, including promoting tumour
cell epithelial-to-mesenchymal transition (EMT) [6],
immune suppression, and stromal myofibroblast dif-
ferentiation [14], its role as a tumour suppressor in the
stages of early carcinogenesis has raised the possibility
that targeting the integrin in the wrong setting might act
to promote, rather than suppress, tumour progression.
Notably, inhibiting αvβ6 in a transgenic model of PDAC
has been shown previously to promote early and late
disease stages in the presence of wild-type SMAD4
[15].
Several studies have emphasized the importance
of cell-mediated mechanical force application in
αvβ6-dependent activation of TGF-β1, whereby
actomyosin-dependent tractive and tensile forces are
applied, via αvβ6, to ECM-associated LAP [3,11–13].
Reorganization of the actin cytoskeleton is integral to
cell migration, with tension transmitted to the ECM
through integrin-containing adhesion complexes at the
cell surface; this is mediated through Rho GTPases
(Rho, Rac, and Cdc42 [16]). Notably, epidermal growth
factor receptor pathway substrate 8 (Eps8) has been
shown to control actin remodelling both directly through
actin capping and bundling and indirectly through acti-
vation of Rac1 [17–19]. Its multiple binding partners,
including actin, Abi1, Sos1, RN-Tre, IRSp53, palladin,
F-actin, and certain integrin β subunits (β1, β3, β5),
indicate that Eps8 sits at the heart of a complex system
regulating actin reorganization [17–21]. Moreover,
Eps8 up-regulation in several cancers, including PDAC,
has been shown to promote a pro-migratory phenotype
[22–24].
In this study, we examined the relationship between
αvβ6-dependent cell invasion and TGF-β1 activation.
Using PDAC (a cancer type with high levels of αvβ6
expression) as a model, we confirmed that both pro-
cesses are primarily regulated by αvβ6. Surprisingly,
we found that motility and TGF-β1 activation have an
inverse relationship, and that function can be biased
towards either process depending on the presence or
absence of Eps8, respectively. We found that Eps8,
when in complex with Abi1/Sos1, promotes Rac1
activation, increasing cell migration and invasion;
targeted siRNA knockdown of Eps8, Sos1 or Rac1
suppressed cell movement, but conversely, increased
αvβ6-dependent activation of TGF-β1. This latter effect
resulted from increased cell tension and was driven by
Rho activation. The loss of motility following Rac1
or Eps8 knockdown was restored if Rho was also
inhibited. Thus, the Eps8/Abi1/Sos1 tricomplex is a
key regulator of αvβ6-dependent tumour cell function,
acting as a molecular switch that alters the balance
between Rac1 and Rho activation, and biasing func-
tion towards a pro-migratory (Rac1-dependent) or
pro-TGF-β1 activation (Rho-dependent) phenotype,
respectively.
Materials and methods
Antibodies and reagents
The antibodies and siRNA sequences used are sum-
marized in the supplementary material, Tables S1 [25]
and S2.
Cell lines and culture
Capan1 and SW1990 cells were cultured in DMEM,
BxPC3, and SU86.86 cells in RPMI; and Panc0403
cells in RPMI supplemented with 10mM HEPES
buffer, 1mM sodium pyruvate, and 0.2U/ml insulin
from bovine pancreas. Media contained 10% fetal
bovine serum and 2mM L-glutamine. The absence of
Mycoplasma was regularly confirmed using PCR. DNA
fingerprinting of the PDAC cell lines (Capan1, BxPC3,
and Panc0403) was performed using the GenomeLab
Human STR Primer Set (Beckman-Coulter Inc, Brea,
CA, USA), and the results were verified against the
COSMIC cell line database, Wellcome Trust Sanger
Institute. Primary pancreatic stellate cells (PPSCs)
were obtained using normal pancreatic tissue from two
patients undergoing pancreatic resection at University
Hospital Southampton (UHS). Appropriate ethical
approval and patient consent were in place (REC No
10/H0502/72).
RNA interference
Cells were transfected with pre-designed, validated,
and optimized siRNA oligonucleotides (supple-
mentary material, Table S2 and Figure S1) using
Oligofectamine™ transfection reagent according to
the manufacturer’s protocol (Invitrogen, Carlsbad, CA,
USA). Functional assays were performed at 24 (organ-
otypic assays) or 48 h (Transwell®/TGF-β activation)
post-transfection.
Transwell® migration and invasion assays
Motility assays were performed using Transwell®
migration inserts (8 μm pore size, polycarbonate mem-
brane; Corning® Costar® Wiesbaden, Germany) as
described previously [10]. For migration assays, the
underside of the inserts was coated with 0.5 μg/ml
latency-associated peptide of TGF-β1 (LAP); for
invasion assays, the top of each insert was coated
with Matrigel (BD Biosciences, San Diego, CA, USA)
diluted 1:1 with DMEM. Cells migrating to/invading the
lower chamber were counted after overnight (migration)
or 72 h incubation (invasion) using a CASY counter
(Sharfe System GmbH, Reutlingen, Germany).
Organotypic cultures
Organotypic cultures were prepared as described previ-
ously and contained 2.5× 105 HFFF2/PPSC cells [26].
2.5× 105 HFFF2/PPSC cells combined with 5× 105
PDAC cells were seeded on top of the gels. The medium
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was changed every 2 days, and the gels were bisected,
fixed, and processed to paraffinwax on day 12. Cell inva-
sion was quantified using ImageJ software.
Immunohistochemistry of tissue microarrays (TMAs)
TMAs were constructed from archival paraffin-
embedded material at UHS. Pancreatic resection
specimens were derived from 75 patients undergoing
pancreatic resection for PDAC between 2005 and
2010. H&E-stained slides were reviewed and triplicate
1mm cylindrical cores selected from representative
areas of each tumour block and arrayed onto a new
recipient paraffin block using a tissue arrayer (Alphelys
Minicore® 3, Plaisir, France). Appropriate ethical
and institutional ethical approval was obtained (REC
No 10/H0502/72). Tissue staining was scored, using
the QuickScore method, as absent/weak or moderate/
strong [27].
Western blotting
Cells were lysed in NP40 lysis buffer (40mM Tris–HCl,
pH 7.4, 1% NP40, 5mM EDTA, 5mM EGTA, 50mM
NaCl, 5mM NaF, and protease inhibitor cocktail).
Lysates containing equal amounts of protein were
electrophoresed in 6–15% SDS-PAGE gels and elec-
troblotted to PVDF membranes (Merck Millipore,
Watford, UK) as described previously [28]. The anti-
bodies used throughout the study are listed in the
supplementary material, Table S1 [25].
Modulation and determination of Rac1 activity
Rac1 activation assays were performed as described
previously [29]. 8× 105 cells were plated 24 h
post-transfection and allowed to settle for 6 h. Cells
serum-starved overnight were lysed on ice following
5min stimulation with EGF (20 ng/ml). Cleared cell
lysates were incubated with GST-PAK-CRIB beads for
1 h at 4 ∘C. Active/total Rac1 levels were analysed by
western blotting.
Transfection with constitutively active EGFP-tagged
Rac1 [Rac1V12-GFP (J Monypenny, GKT, London,
UK)] or vector control (pEGFP-C2; Invitrogen) was
performed using Fugene HD transfection reagents
(Promega, Madison, WI, USA) following the manufac-
turer’s protocol.
Determination of Rho activity
Active/total RhoA levels were measured in 2× 106 cells
48 h post-transfection using the Rho G-LISA activation
assay kit and the Total RhoA ELISA kit (Cytoskele-
ton, Denver, CO, USA) following the manufacturer’s
protocol.
Phalloidin staining of PDAC cells
PDAC cells (4× 105, 24 h post-transfection) were plated
on 13-mm LAP-coated coverslips and serum-starved
overnight. Immunofluorescence staining was per-
formed using the actin cytoskeleton staining kit (Merck
Milllipore) according to the manufacturer’s instruc-
tions. Scoring of actin stress-fibre formation was
performed in randomly selected, fully spread cells,
in a minimum of ten fields per condition. Mean flu-
orescence intensity (arbitrary units) was calculated
using ImageJ.
Traction force microscopy
Ultrathin polyacrylamide hydrogels, embedded with
FluoSpheres® carboxylate-modified 0.2 μm fluorescent
(505/515) microspheres (Thermo Fisher Scientific,
Waltham, MA, USA), were generated as described
previously [30–32] with some modifications. Briefly,
NaOH-washed 14mm glass-bottomed dishes (Mat-
Tek, Ashland, MA, USA) were amino-silanated
with 0.5% 3-aminopropyltrimethyoxysilane and
incubated with glutaraldehyde for 30min. 20 μl of
FluoSpheres® suspension was added to 500 μl of 3%
or 9% acrylamide/bis-acrylamide (37.5:1) solutions.
6 μl of polyacrylamide FluoSpheres® suspension was
immediately added to amino-silanated surfaces, over-
laid with acid-washed 13mm coverslips, and allowed
to polymerize, to produce hydrogels with predicted
elastic moduli of 400 Pa and 12.5 kPa. Hydrogels
were treated with 0.2mg/ml sulfo-SANPAH (Thermo
Fisher Scientific), photoactivated with 365 nm UV light,
washed with 50mM HEPES (pH 8.5), and coated with
0.5 μg/ml LAP.
Cells were plated on LAP-coated hydrogels for
more than 14 h, prior to imaging on a 3i Marianas
spinning-disk confocal microscope. For each condition,
multipoint bright-field and 488 nm image stacks (>
12 μm) were acquired for each position. After imaging,
cells were lysed with 1% SDS and multipoint positions
re-imaged to obtain unstrained bead positions.
Image analysis was performed using Fiji soft-
ware on z-position-aligned pre- and post-lysis stacks.
Force-induced bead displacement and gel deforma-
tion were measured by particle image velocitometry
(PIV) using the iterative PIV (advanced) plugin [30] by
three-pass interrogation (third pass parameters: PIV3
interrogation window size= 40 px; SW3 search window
size= 80 px; VS3 vector spacing= 20 px). Traction
forces and vectors were calculated by Fourier transform
traction cytometry (FTTC) using the FTTC plugin, pre-
dicted gel elastic moduli, and a Poisson ratio of 0.5 [30].
Co-culture experiments
HFFF2 cells were plated in an eight-well
Permanox-coated chamber slide (Thermo Fisher Scien-
tific, Waltham, MA, USA) at a density of 104 cells per
well. After 48 h, 104 cancer cells per well were plated
on top of the fibroblasts. After 72 h, cells were fixed
with 4% formaldehyde. Stress-fibres were visualized
with α-smooth muscle actin (αSMA; Dako, Ely, UK),
and cancer cells with cytokeratin (Dako) antibody using
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a Zeiss Axiovert 200 fluorescence microscope [at 40×
magnification using an Orca-ER digital camera (Hama-
matsu, Shizuoka, Japan)]. αSMA mean fluorescence
intensity (arbitrary units) was calculated using ImageJ
software.
TGF-β activation assay
TGF-β1 activation was measured by co-culture of
mink lung epithelial cells (MLECs) stably expressing
a TGF-β1-responsive luciferase reporter construct
(5× 104 cells per well) with PDAC cells (12× 104 cells
per well) in serum-free conditions [28].
Statistical analysis
For functional assays, differences between experimen-
tal groups were examined with Student’s t-tests (Prism
4, GraphPad software). Statistical significance was
indicated in the following way: *p< 0.05, **p< 0.01,
***p< 0.001, ****p< 0.0001. Bars indicate the stan-
dard deviation (SD) unless otherwise stated. Differences
between immunohistochemical staining were examined
using Fisher’s exact test.
Results
αvβ6 is overexpressed in PDAC and promotes
tumour invasion and TGF-β1 activation
αvβ6 expression has been reported to be up-regulated in
PDAC [7]. Our analysis of 75 tumours similarly showed
significantly increased αvβ6 expression in PDAC tis-
sue (75% moderate/strong expression) compared with
surrounding tissue (24% moderate/strong expression)
(Figure 1A). Five PDAC cell lines were screened for
expression of the αv and β6 integrin subunits; three
(Capan1, BxPC3, and Panc0403) showed high expres-
sion of both subunits (Figure 1B; supplementary mate-
rial, Figure S2A) and were chosen for use in functional
assays. All three cell lines showed αvβ6-dependent
migration and invasion, which were suppressed by an
inhibitory αvβ6 antibody, 63G9 (Figure 1C, D; sup-
plementary material, Figure S2B). We next performed
TGF-β1 activation assays and found that only cell lines
with high αvβ6 expression showed robust activation
of the cytokine; this was significantly reduced follow-
ing αvβ6 blockade (Figure 1E; supplementary material,
Figure S3). We then examined the role of αvβ6 in pro-
moting collective tumour invasion in a 3D organotypic
model using either human fetal foreskin fibroblasts
(HFFF2) or primary pancreatic stellate cells (PPSCs)
as the stromal component. BxPC3 and Panc0403 cells
invaded well in the presence of either stromal cell type,
with invasion significantly inhibited following β6 siRNA
knockdown (Figure 1F). Capan1 cells do not invade in
thismodel. These collective results confirm a central role
for αvβ6 in tumour cell motility and TGF-β1 activation
in pancreatic cancer.
Eps8 is overexpressed in PDAC, promotes
αvβ6-dependent PDAC motility, but suppresses
αvβ6-dependent TGF-β1 activation
Similar to αvβ6, Eps8 has also been reported to be
up-regulated in several carcinomas [22,23,24,29]. We
examined Eps8 expression in the cohort of 75 patients
and found significant up-regulation in PDAC tissue
(72%) compared with surrounding pancreatic tissue
(26%) (Figure 2A). Of the five PDAC cell lines exam-
ined, the three αvβ6-positive lines expressed high levels
of Eps8 (Figure 2B). We next investigated the role of
Eps8 in αvβ6-dependent migration, invasion, and TGF-β
activation. We found that Eps8 siRNA knockdown sig-
nificantly inhibited both αvβ6-dependent migration
(Figure 2C; supplementary material, Figure S4A)
and invasion (Figure 2D), whereas overexpression of
Eps8–EGFP induced cell motility (supplementary
material, Figure S5A). Unexpectedly, down-regulation
of Eps8 induced, rather than inhibited, αvβ6-dependent
TGF-β1 activation (Figure 2E; supplementary material,
Figure S4B). Consistent with this, overexpression of
Eps8–EGFP suppressed activation of the cytokine
(supplementary material, Figure S5B, C). These data
suggest that αvβ6 regulates both PDAC motility and
TGF-β1 activation, and that the presence of Eps8 shifts
the balance of these functions towards motility.
Eps8 mediates αvβ6-dependent functions via Rac1
activation
Eps8 siRNA knockdown had no effect on αvβ6 lev-
els/activation or cell adhesion (supplementary material,
Figure S6), suggesting that Eps8-dependent TGF-β1
activation was not due to altered αvβ6 expression
or function. Eps8 modulates the cytoskeleton via its
actin-binding and -capping activity, and through reg-
ulation of signalling pathways, including activation
of the Rho GTPase, Rac1, when part of a tricomplex
with Abi1 and Sos1 [20]. To determine whether Eps8
promotes Rac1 activation in PDAC cells, we performed
Rac1 pull-down assays using epidermal growth factor
(EGF), a stimulus that amplifies αvβ6-specific motility
and Rac1 activation in these cell lines (supplemen-
tary material, Figure S7). Eps8 knockdown suppressed
EGF-dependent Rac1 activation (Figure 3A), which was
similarly inhibited by knockdown of β6 (supplementary
material, Figure S7C). Further investigation suggested
involvement of the Eps8/Abi1/Sos1 tricomplex; we
found up-regulated expression of the Rac1 guanine
nucleotide exchange factor, Sos1, in PDAC tissue and
cell lines (supplementary material, Figure S8A, B), and
Sos1 siRNA knockdown suppressed EGF-induced Rac1
activation (supplementary material, Figure S8C). In
motility assays, inhibition of Rac1 [siRNA, Figure 3B;
Rac inhibitor NSC23766 (Merck Millipore), supple-
mentary material, Figure S9A] significantly inhibited
migration, and this was restored by expression of con-
stitutively active Rac1V12 (Figure 3C). Inhibition of
Sos1 also suppressed migration (siRNA, supplementary
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Figure 1. αvβ6 integrin is overexpressed in PDAC and promotes motility and TGF-β activation. (A) Representative images of immunohisto-
chemistry staining of αvβ6 in PDAC (ii; tumour) and surrounding (i; uninvolved) tissue. The table to the right shows the staining intensity
using the QuickScore method. (B) Western blot showing β6 expression in PDAC cell lines. The human oral squamous cell carcinoma cell line
VB6 was used as a positive control. Equal loading was confirmed by HSC70. (C) Transwell® migration towards LAP and (D) Matrigel invasion
of αvβ6-positive PDAC cells in the presence or absence of the αvβ6 blocking antibody 63G9. Diagrams represent the mean number of
migrating/invading cells per well expressed as a % of Ctl (BSA)± SD. n= 3 (migration); n= 4 (invasion); *p< 0.05; **p< 0.01; ***p< 0.001.
(E) PDAC cells induce activation of TGF-β1 in an MLEC TGF-β activation assay, which is inhibited by 63G9. Diagram represents the mean
relative light units expressed as a % of MLECs ± SD. n= 6; ****p< 0.0001. (F) Cytokeratin staining of organotypic gels showing invasion
of non-targeting (Ctl) or β6 siRNA-transfected BxPC3 and Panc0403 cells in the presence of HFFF2 fibroblasts and primary pancreatic
stellate cells (PPSCs). Representative images are shown. Arrowheads indicate invading tumour islands. Note the reduced invasion depth in
organotypic cultures with β6 siRNA-transfected cells. Diagrams showing the mean invasion depth of three independent sections analysed
by ImageJ software expressed as a % of Ctl± SD. n= 3; *p< 0.05; **p< 0.01; ***p< 0.001. Western blots confirm down-regulation of β6.
Equal loading was confirmed by HSC70. Numbers below the blots indicate the densitometry values measured using ImageJ normalized to
HSC70 and expressed as a ratio to Ctl.
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Figure 2. Eps8 is overexpressed in PDAC and promotes motility but inhibits TGF-β activation. (A) Representative images of immunohisto-
chemistry staining of Eps8 in PDAC (ii; tumour) and surrounding (i; uninvolved) tissue. The table shows the staining intensity using the
QuickScore method. (B) Western blot showing Eps8 expression in five PDAC cell lines. The human oral squamous cell carcinoma cell line
VB6 was used as a positive control. Equal loading was confirmed by HSC70. (C) Transwell® migration towards LAP and (D) Matrigel invasion
of αvβ6-positive PDAC cells following Eps8 knockdown in the presence or absence of the αvβ6 blocking antibody 63G9. Diagram represents
the mean number of migrating/invading cells per well expressed as a % of Ctl (BSA)± SD. n= 3 (migration); n= 4 (invasion); *p< 0.05;
***p< 0.001; ****p< 0.0001. (E) TGF-β1 activation by PDAC cells following Eps8 knockdown measured by an MLEC TGF-β activation assay, in
the presence or absence of the αvβ6 blocking antibody 63G9. Diagram represents the mean relative light units expressed as a % of MLECs
± SD. n= 6; ***p< 0.001; ****p< 0.0001. Western blots in C–E confirm down-regulation of Eps8. Equal loading was confirmed by HSC70.
Numbers below the blots indicate the densitometry values measured using ImageJ normalized to HSC70 and expressed as a ratio to Ctl.
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material, Figure S8D). Double knockdown of Eps8 and
Rac1 did not produce a greater level of inhibition than
that of the individual proteins (supplementary mate-
rial, Figure S9B), suggesting that they function in the
same pathway. PDAC cell invasion was also Rac1- and
Sos1-dependent (Figure 3D; supplementary material,
Figure S8E).
Next, we examined the role of the Rac pathway
in TGF-β1 activation. Inhibition of Rac1 (siRNA,
Figure 3E; NSC23766, supplementary material,
Figure S9C) or Sos1 (siRNA, supplementary mate-
rial, Figure S8F) resulted in a significant increase in
αvβ6-dependent TGF-β1 activation. Similar to migra-
tion assays, double knockdown of Eps8 and Rac1 did
not result in an additive effect (supplementary material,
Figure S9D). These results provide evidence that Eps8,
its binding partner Sos1, and their downstream effector
Rac1 all promote αvβ6-dependent PDAC motility, yet
inhibit αvβ6-dependent TGF-β1 activation.
Eps8 suppresses stress-fibre formation and cell
traction
αvβ6-mediated TGF-β1 activation is thought to require
application of actomyosin-dependent force on LAP to
induce a conformational change in the TGF-β1 latent
complex [3,11–13]. Initially, we examined intracel-
lular stress-fibre formation as a surrogate measure
of cytoskeletal tension. Eps8 or Rac1 knockdown
led to a significant increase in stress-fibre formation
measured by mean fluorescence intensity of phal-
loidin staining (Figure 4A; supplementary material,
Figure S10). We next examined whether Eps8 modu-
lates tractive force using traction force microscopy
to quantify cell-mediated force applied to LAP
substrates of differing rigidities. siRNA-mediated
knockdown of Eps8 in BxPC3 cells substantially
increased the tractive forces, irrespective of substrate
rigidity (Figure 4B). Together, these data suggest that
Eps8-dependent Rac1 activation inhibits TGF-β1 activa-
tion through suppressing the force applied to the latent
TGF-β1 complex.
Eps8 suppression promotes Rho activation
and function
The role of Rho kinases in αvβ6-dependent TGF-β
activation has previously been described [11,33,34],
and Rac1 signalling has been shown to antagonize Rho
activity directly [35,36]. We therefore hypothesized that
Eps8/Rac1 suppression may promote RhoA activation,
promoting increased cell tension. RhoA activation
assays confirmed an increase in activation follow-
ing down-regulation of Eps8 (Figure 5A). To further
examine the functional relationship between Rac1 and
Rho signalling, we performed migration (Figure 5B,
C) and invasion assays (Figure 5D, E) using the spe-
cific cell-permeable exoenzyme C3 transferase-based
selective Rho inhibitor (CT04; Cytoskeleton) following
siRNA knockdown of Eps8 or Rac1. Treatment of
Eps8-knockdown cells with this inhibitor led to reduced
stress-fibre formation, a readout of Rho activation
(supplementary material, Figure S11). We also found
that Rho inhibition following either Eps8 or Rac1
knockdown restored motility (Figures 5B–E). This
suggests that reduced motility following Eps8/Rac1
suppression is the result, at least in part, of an increase
in Rho activation and not simply loss of Rac activity.
As anticipated, TGF-β1 activation assays showed the
reverse effect; the increase in αvβ6-dependent TGF-β1
activation seen following Eps8/Rac1 siRNA knockdown
was suppressed by Rho inhibition (Figures 5F, G). Sim-
ilarly, inhibition of the basal levels of Rho activation
induced cell migration and inhibited TGF-β1 activation
(supplementary material, Figure S12). Our results show
that the presence/absence of Eps8 signalling modulates
different αvβ6-dependent functions, through differential
regulation of Rho GTPases; Eps8 promotes Rac1 activa-
tion and cell motility, yet suppression of this signalling
pathway leads to an increase in Rho activation, which
promotes TGF-β1 activation.
Differential effects of Eps8 on tumour–stromal
interactions
In Transwell® assays, the pro-migratory effect of Eps8
on cell invasion and migration was consistent across
the different cell lines (Figure 2C, D) and independent
of potential TGF-β1-dependent effects on cell move-
ment. However, TGF-β1 also promotes myofibroblast
transdifferentiation of stromal cells [37]; therefore,
we examined the effect of Eps8 knockdown in 3D
organotypic models containing fibroblasts or stellate
cells. Surprisingly, we observed a differential effect of
Eps8 on PDAC cell invasion; Eps8 suppression signif-
icantly reduced organotypic invasion of BxPC3 cells,
but promoted invasion of Panc0403 cells (Figure 6A;
supplementary material, Figure S13). A similar effect
was observed following Rac1- and Sos1-siRNA knock-
down (supplementary material, Figure S14). TGF-β1
activation can promote invasion through modulat-
ing stromal myofibroblast differentiation [38], and
notably, immunohistochemical analysis highlighted a
distinctive subepithelial layer of αSMA-positive (acti-
vated) myofibroblasts in Panc0403 organotypic cultures
(Figure 6B) that was not present in BxPC3 cultures.
This desmoplastic reaction was enhanced following
down-regulation of Eps8 and revealed a clear interac-
tion between αSMA-positive fibroblasts and invading
tumour islands. Treatment of HFFF2 fibroblasts with
hrTGF-β1 drives their differentiation from fibrob-
lasts to contractile, αSMA-positive myofibroblasts
(Figure 6D); however, while both BxPC3 and Panc0403
cells activate TGF-β1, direct comparison revealed that
the levels of activation were significantly higher in
Panc0403 cells (Figure 6C), possibly explaining the
desmoplastic reaction in organotypic cultures with this
cell line. Consistent with this, co-culture experiments
of HFFF2 fibroblasts with Eps8 knockdown Panc0403
cells showed significantly increased myofibroblast
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Figure 3. Eps8-promoted Rac1 activation induces PDAC cell motility and inhibits TGF-β activation. (A) Results of a GST pull-down assay
using GST-PAK-CRIB-coated Sepharose beads showing EGF-induced Rac1 activation in PDAC cells transfected with non-targeting (Ctl)
or Eps8 siRNA. Eps8 knockdown in the same lysates was confirmed on separate western blots. (B) Transwell® migration of PDAC cells
transfected with non-targeting (Ctl) or Eps8 siRNA towards LAP. Diagram represents the mean number of migrating cells per well expressed
as a % of Ctl (BSA)± SD. n= 3; *p< 0.05; **p< 0.01; ***p< 0.001. (C) Overexpression of the constitutively active mutant of Rac1 (RacV12)
restores migration of PDAC cell lines compared with empty vector control (EV) following Eps8 knockdown. Diagram represents the mean
number of migrating cells per well expressed as a % of EV (BSA)± SD. n= 3; *p< 0.05; **p< 0.01; ***p< 0.001. (D) Matrigel invasion of
PDAC cells was significantly inhibited by Rac1 knockdown. Diagram represents the mean number of invading cells per well expressed
as a % of Ctl± SD. n= 4; **p< 0.01; ***p< 0.001. (E) Rac1 knockdown induces activation of TGF-β1 compared with non-targeting (Ctl)
siRNA-transfected cells in an MLEC TGF-β activation assay. Rac1-induced TGF-β1 activation was inhibited by the αvβ6 blocking antibody
63G9. Diagram represents the mean relative light units expressed as a % of MLECs ± SD (Capan1/BxPC3 plotted on left, Panc0403 plotted
on right Y -axis). n= 6; *p< 0.05; ****p< 0.0001. Western blots in B–E confirm down-regulation of Rac1. Equal loading was confirmed by
HSC70. Numbers below the blots indicate the densitometry values measured using ImageJ normalized to HSC70 and expressed as a ratio
to Ctl.
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Figure 4. Inhibition of Eps8 promotes stress-fibre formation and force application on LAP. (A) PDAC cells were transfected with either
non-targeting (Ctl) or Eps8/Rac1 siRNA, plated on 0.5 μg/ml LAP-coated coverslips, and after an overnight incubation stained with
phalloidin-FITC (red) to visualize stress-fibre formation. DAPI (blue) was used as a nuclear counterstain. Cells were visualized using ×100
optical zoom. Exposure of images was uniformly enhanced across images to aid better visibility. Actin stress-fibre formation was quantified
in randomly selected fully spread cells using ImageJ. Cells were selected as regions of interest (ROIs) and the phalloidin mean fluorescence
intensity was quantified within the identified ROIs. Diagram represents the mean relative fluorescence intensity per field expressed as
a % of Ctl± SD. n= 10 fields per condition; *p< 0.05; **p< 0.01; ***p< 0.001. Western blots confirm down-regulation of Eps8 or Rac1
following siRNA transfection. Equal loading was confirmed by HSC70. Numbers below the blots indicate the densitometry values measured
using ImageJ normalized to HSC70 and expressed as a ratio of Ctl. (B) Cell-mediated forces applied to 0.5 μg/ml LAP-coated substrates, by
BxPC3 cells transfected with non-targeting (Ctl) or Eps8-targeting (Eps8) siRNA, measured by traction force microscopy on hydrogels with
predicted elastic moduli of 0.4 kPa (i, ii) and 12.5 kPa (iv, v). Data are represented as interrogation window force vectors (i and iv) and force
magnitude maps (ii and v) for individual cells, and graphs (iii) showing the mean traction force magnitude per field ± SEM. n= 12–20
fields per condition; **p< 0.01; ***p< 0.001. Data show a representative experiment of three independent repeats.
differentiation (Figure 6E). Thus, although Eps8 knock-
down suppresses both Panc0403 and BxPC3 motility
in Transwell® assays, the increased stromal response
induced by the Panc0403 cells is sufficient to over-
ride this inhibition (which remains in the BxPC3
cells, due to their lack of ability to modulate the
adjacent stroma).
Discussion
Overexpression of αvβ6 is prognostic in various cancers
[29,38,39]; αvβ6 signalling promotes tumour invasion
through different mechanisms, regulating protease
expression and also activating the cytokine TGF-β1,
which promotes tumour cell EMT and stromal myofi-
broblast differentiation [40]. Several studies suggest that
αvβ6 targeting may be an attractive therapeutic option;
targeting αvβ6 in pre-clinical breast cancer models
using a monoclonal antibody, 264RAD, either alone or
in combination with the HER2 inhibitor trastuzumab,
resulted in significant inhibition of disease progression
[9,41]. However, targeting αvβ6 in human disease is
complicated by its role in TGF-β1 activation, which
may act as a tumour suppressor through effects on
cell cycle regulators [42]. This has led to suggestions
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Figure 5. Eps8 and Rac1 regulate PDAC cell motility and TGF-β activation by modulating RhoA. (A) PDAC cells were transfected with
non-targeting (Ctl) or Eps8-targeting siRNA and RhoA activation was measured using a colorimetric G-LISA assay 48 h post-transfection.
Diagrams represent the mean active RhoA levels normalized to total RhoA levels expressed as a % of Ctl± SD. n= 3; **p< 0.01;
ns= non-significant. (B, C) Transwell® migration and (D, E) Matrigel invasion of PDAC cells transfected with non-targeting (Ctl) or Eps8-
(B, D) or Rac1- (C, E) targeting siRNA were measured following pretreatment with vehicle control or 0.5 μg/ml CT04 Rho inhibitor (Rhoi).
Diagrams represent the mean number of migrating/invading cells per well expressed as a % of Ctl (BSA)± SD. n= 3 (migration); n= 4
(invasion); *p< 0.05; **p< 0.01; ***p< 0.001; ns= non-significant. (F, G) PDAC cells transfected with non-targeting (Ctl) and Eps8- (F) or
Rac1- (G) targeting siRNA were pretreated with vehicle control or 0.5 μg/ml CT04 Rho inhibitor (Rhoi), after which they were plated on
top of MLEC cells in the absence of the inhibitor. Diagrams represent the mean relative light units expressed as a % of MLECs ± SD. n= 6;
**p< 0.01; ***p< 0.001; ****p< 0.0001. Western blots confirm down-regulation of Eps8 (A, B, D, F) and Rac1 (C, E, G). Equal loading was
confirmed by HSC70. Numbers below the blots indicate the densitometry values measured using ImageJ normalized to HSC70 and expressed
as a ratio to Ctl.
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Figure 6. Differential activation of stromal cells by PDAC cell lines. (A, B) BxPC3 and Panc0403 cells were transfected with either
non-targeting (Ctl) or Eps8-targeting siRNA and organotypic invasion assays were performed in the presence of HFFF2 fibroblasts over
a period of 12 days. A representative image of a cytokeratin- (Ai) or the myofibroblast marker α-smooth muscle actin-stained (αSMA; Bi)
section is shown. Arrowheads in Bi point at the interaction between invading tumour islands and activated fibroblasts. (Aii) Diagram showing
the relative mean invasion depth of three independent sections analysed by ImageJ software expressed as a % of Ctl± SD. **p< 0.01. (Bii)
Diagram representing the αSMA-positive area expressed as a % of Ctl± SD analysed by the Trainable Weka segmentation plugin in the
ImageJ software. n= 7; ****p< 0.0001; ns= non-significant. Western blots confirm down-regulation of Eps8. Equal loading was confirmed
by HSC70. Numbers below the blots indicate the densitometry values measured using ImageJ normalized to HSC70 and expressed as a
ratio of Ctl. (C) TGF-β1 activation by BxPC3 and Panc0403 cells was measured by the MLEC TGF-β activation assay and showed increased
TGF-β1 activation by Panc0403 cells. Diagram shows the results of seven independent experiments and represents the mean relative light
units expressed as a % of MLECs ± SEM; **p< 0.01. (Di) HFFF2 fibroblasts were treated or not with hrTGF-β1 for 48 h and αSMA-positive
stress-fibres (green) were visualized by confocal microscopy. DAPI (blue) was used as a nuclear counterstain. Stress-fibre formation was
quantified in randomly selected fields using ImageJ. Diagram represents the mean relative fluorescence intensity per field expressed as a
% of Ctl± SD. n= 6 fields per condition; ****p< 0.0001. (Dii) TGF-β1-induced αSMA expression was confirmed using western blotting. (E)
Panc0403 cells were transfected with non-targeting (Ctl) or Eps8-targeting siRNA and were plated on top of HFFF2 fibroblasts for 72 h.
Stress-fibre formation in the fibroblasts was detected by staining for αSMA (green); cancer cells were identified by cytokeratin staining (red)
using confocal microscopy. DAPI (blue) was used as a nuclear counterstain. Stress-fibre formation was quantified in randomly selected fields
using ImageJ. Diagram represents the mean relative fluorescence intensity per field expressed as a % of Ctl± SD. n= 6 fields per condition;
**p< 0.01. Western blots in Aii and E confirm down-regulation of Eps8. Equal loading was confirmed by HSC70. Numbers below the blots
indicate the densitometry values measured using ImageJ normalized to HSC70 and expressed as a ratio of Ctl. Data show a representative
experiment of at least three independent repeats.
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that αvβ6 should not be targeted in tumours retaining
canonical TGF-β1 signalling. For example, blockade
of TGF-β1 or αvβ6 in a genetically engineered KRAS
PDAC mouse model was found to accelerate disease
progression in Smad4-expressing tumours [15]. How-
ever, in tumours with homozygous deletion of SMAD4,
the tumour-suppressive effect of αvβ6 was lost [15].
These data highlight the need to dissect the molecular
mechanisms regulating functions of this integrin.
While αvβ6 has been shown to promote motility and
TGF-β1 activation in a number of tumour types, no
study has examined yet how these functions are linked.
Our previous work in oral squamous cell carcinoma
showed that Eps8 regulates integrin-mediated invasion
[29], and we therefore examined more broadly the role
of Eps8 in regulating αvβ6-dependent functions. PDAC
has been reported to overexpress both αvβ6 and Eps8
[7,23], and consistent with these studies, we found that
around 70% of tumours expressed αvβ6 and Eps8 at
moderate/high levels (Figures 1A and 2A). Similar to
other cancer types, we found that αvβ6 promotes cancer
cell motility and TGF-β1 activation [37,43,44], with
suppression of αvβ6 resulting in complete inhibition of
these processes.
Eps8 has been shown previously to promote the
migration of PDAC cells [23]. We found that this
motility-promoting effect appears to be through mod-
ulating activation of Rac1 via the Rac1–GEF Sos1,
as we found that suppression of Eps8, Sos1 or Rac1
independently inhibited PDAC migration/invasion. It is
therefore probable that Eps8 regulates αvβ6-dependent
motility through the Eps8/Abi1/Sos1 tricomplex,
although Eps8/Sos1 has also been shown to complex
with CIIA, a protein associated with regulation of
EMT and cell migration, to promote Rac1 activation
independent of Abi1 [45]. Notably, the inhibitory
effect of Eps8 knockdown on cell motility resulted
from differential regulation of Rac1 and RhoA
activation (Figure 5); reduced migration following
Eps8/Rac1 inhibition could be restored either by
expressing constitutively active Rac1 or inhibiting
Rho signalling. Rac1 has previously been reported
to antagonize Rho activity directly [35] and regulate
β1 integrin-dependent motility in PDAC and colon
cancer cells [46,47]. A recent study using computa-
tional modelling also identified a MEK-driven feedback
loop where inhibition of Eps8/Abi1/Sos1-mediatied
Rac1 activation following Eps8 knockdown leads to
increased Rho activation [48]. Unexpectedly, PDAC
cells remained motile following inhibition of both
Rac1 and Rho; several studies have similarly found
that cell migration is possible in the absence of both
GTPases [49–51].
Notably, Eps8 acted as a negative regulator of
αvβ6-dependent TGF-β1 activation through the same
mechanism (Figure 3), and both Rac1 and Sos1 knock-
down similarly induced TGF-β1 activation (Figure 5;
supplementary material, Figure S8). The role of Rho
kinases in αvβ6-dependent TGF-β activation has been
implicated in several studies using ROCK inhibitors
[11,33,34]. It has also been hypothesized that increased
cell tension generated by Rho activation results in a
conformational change in LAP and exposure of active
TGF-β1 [13]. Our findings support this precept, and
to the best of our knowledge, this is the first study to
provide a direct link between Rac1/Rho activity and
αvβ6-dependent TGF-β activation, showing that cells
can apply mechanical forces to LAP and that the bal-
ance between Rac1 and Rho GTPase activation favours
different αvβ6-dependent cell functions.
Our results from 3D organotypic cultures highlight
the problems of studying tumour cell motility in iso-
lation and stress the important role of stromal cells
in the invasive process. In Transwell® assays, Eps8
knockdown consistently suppressed PDAC motility;
however, Eps8 knockdown in organotypic culture
promoted the invasion of Panc0403 cells. This was
modulated through increasing TGF-β1 activation,
which induced myofibroblastic transdifferentiation
of fibroblasts/stellate cells (Figure 6; supplemen-
tary material, Figure S13). Rac1 or Sos1 knockdown
produced a similar effect (supplementary material,
Figure S14). This demonstrates how TGF-β1 activa-
tion can indirectly promote invasion through stromal
regulation. Given the notion that αvβ6-targeting should
be avoided in tumours that retain canonical signalling,
it is noteworthy that αvβ6 inhibition significantly
suppressed the invasion of Panc0403 cells that retain
wild-type SMAD4.
In summary, αvβ6 is a promising target for tumour
therapy, but given its different functional effects,
detailed knowledge of the underlying molecular mech-
anisms regulating these processes is required. We have
shown that the balance in activation of Rho and Rac1
biases function towards TGF-β1 activation or motility,
respectively, with the presence or absence of Eps8
acting as a molecular switch that alters the balance
of GTPase activation within the cell. In late-stage
disease, both αvβ6-dependent functions are likely
to be tumour-promoting; however, we can specu-
late that in premalignant disease, the bias towards
an Eps8-expressing, invasive phenotype may help to
promote malignant transformation.
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